Cancer Risk Reduction Strategies for BRCA 1/2

Overview

Featured Article

Kurian AW, Sigal BM, Plevritis SK; Survival Analysis of Cancer Risk Reduction Strategies for BRCA1/2 Mutation Carriers. J Clin Oncol 2009;22:1-10

Expert Reviews

Methodological Review: Steve Latosinsky MD, MSC, FRCSC, Department of Surgery, University of Western Ontario
Clinical Review: Rona Cheifetz MD, MEd, FRCSC, Department of Surgery, University of British Columbia
Clinical Review: Lee Wilkie MD, FACS, Department of Surgery, University of Wisconsin Health System

Supplementary Article

Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature. VII. How to Use a Clinical Decision Analysis. JAMA 1995;273(16):1292-95

Richardson WS, Detsky AS, for the Evidence-Based Medicine Working Group. Users’ Guides to the Medical Literature. VII. How to Use a Clinical Decision Analysis. JAMA 1995;273(20):1610-13

Questions

  1. What is the clinical question being addressed?
  2. Were all of the realistic clinical strategies compared?
  3. Were all clinically relevant outcomes considered?
  4. Was an explicit and sensible process used to identify, select and combine the evidence into probabilities?
  5. Were the utilities obtained in an explicit and sensible way from credible sources?
  6. Was the potential impact of any uncertainty in the evidence determined in the baseline analysis?
  7. Does one strategy result in a clinically important gain for patients?
  8. How strong is the evidence used in the analysis?
  9. Could the uncertainty in the evidence change the results?
  10. State the conclusion. Have the authors addressed the clinical question posed?
  11. Does the evidence support the conclusion?